Timeline of privileges regarding the commercialization and use of knowledge. Part 2: 1980 to 1999
Draft
This is work in progress, and is part of a larger project on timelines. This particular timeline is unfinished, and may contain errors.
Search Results for: car t
Lunch with the ACTA negotiators, August 17, 2010
On Tuesday, August 17, 2010, USTR organized a lunch between ACTA negotiators and civil society NGOs. There was not much notice. We received our invite to the lunch last Thursday. Representatives from KEI, Public Citizen, Oxfam, Public Knowledge and the American University program on intellectual property attended the event.
U.S. Department of State cables regarding Brazil and pharmaceutical patents and prices – 1986-1987
Background
Beginning in 1985, the United States government (USG) diplomatic and trade officials have engaged in wide ranging activities aimed at changing global norms for the protection of intellectual property rights, with a particular emphasis on the IPR protections for pharmaceutical products.
This note reports on U.S. Department of State cables sent in 1986 and 1987, that discussed the U.S. government efforts to change policies in Brazil on the intellectual property protection for pharmaceutical products. The cables have been obtained by KEI with a FOIA request.
Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010
Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 KEI Research Note 2010:4 August 12, 2010 Anne Mira Guha Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 1. Introduction Ritonavir is… Continue Reading
The US Orphan Drug Tax Credit
From the FDA page on the Orphan Drug Tax Credit. Incentives TAX CREDIT (See Footnote 1 below) FOR TESTING EXPENSES FOR DRUGS FOR RARE DISEASES OR CONDITIONS Introduction Section 45C of the Internal Revenue Code of 1954 allows a credit… Continue Reading
The US Orphan Drug Tax Credit
From the FDA page on the Orphan Drug Tax Credit.
IncentivesTAX CREDIT
(See Footnote 1 below)
FOR TESTING EXPENSES FOR
DRUGS FOR RARE DISEASES OR CONDITIONSIntroduction
Section 45C of the Internal Revenue Code of 1954 allows a credit against tax, up to 50 percent of certain clinical testing expenses related to the use of a drug for a rare disease or condition after it is designated as an orphan drug.Notes on the 2004 to 2009 United States Food and Drug Administration Approval of New Molecular Entities (NMEs)
(Cite as Molly Redfield Ward, Notes on the 2004 to 2009 United States Food and Drug Administration Approval of New Molecular Entities (NMEs), KEI Research Note 2010:3) A PDF version of this document is available here. Notes on the 2004… Continue Reading
Notes and data points for prices of orphan products
February 22, 2010., Matthew Herper, “The World’s Most Expensive Drugs,” Forbes. Genzyme’s web page on the cost of treatment. Some data points on Fabrazyme prices. 2004 prices for Replagal 2001 prices for Cerezyme. Myozyme/Lumizyme A 2007 Canadian analysis of (50… Continue Reading
Written submission U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) Hearing on Treating Rare and Neglected Pediatric Diseases: Promoting the Development of New Treatments and Cures
Written submission U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) Hearing on Treating Rare and Neglected Pediatric Diseases: Promoting the Development of New Treatments and Cures, On the topic of Direct funding, subsidies and incentives for the development… Continue Reading
Transparency, cost benefit analysis and de-linkage of cost of R&D from price of the products for Rare and Neglected Pediatric Diseases
Written submission U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) Hearing on Treating Rare and Neglected Pediatric Diseases: Promoting the Development of New Treatments and Cures On the topic of Transparency, cost benefit analysis and de-linkage of cost… Continue Reading